---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-018764"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:24:44.435679+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma FY2023 net loss $117.7M; LIFT-AD enrollment complete; data H2 2024

## Summary
- Net loss $117.7M ($3.09/sh) vs $95.6M ($2.53/sh) in FY2022; R&D spend rose to $93.8M.
- Cash and investments $147.4M as of Dec 31, 2023, down from $245.2M at end of 2022.
- Phase 2/3 LIFT-AD trial (fosgonimeton) enrollment completed (~315 pts); topline data expected H2 2024.
- First-in-human study of ATH-1105 for ALS on track to initiate in H1 2024.
- Adopted 2024 Inducement Plan reserving 750,000 shares; appointed COO/Chief Dev Officer and Chief People Officer.

## SEC filing metadata
- accession: 0000950170-24-018764
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/0000950170-24-018764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/atha-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-018764
- JSON: https://secwatch.observer/filing/0000950170-24-018764.json
- Plain text: https://secwatch.observer/filing/0000950170-24-018764.txt

## Key facts
- Earnings Releases
  LeonaBio, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/0000950170-24-018764-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.